You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A universal eye drop adherence monitor to measure and improve adherence to ocular medications

    SBC: Universal Adherence LLC            Topic: N

    Project Summary Abstract Universal Adherence is an emerging medical device company dedicated to improving adherence to ocular medications through innovative technical solutionsOur proposed Devers Drop DeviceDwill accurately track when a patient removes an eye drop bottle capcommunicate usage data wirelessly to a database that researchers can accessand send alerts to patients when a medication is d ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Yellow Fever Vaccine for a Vulnerable Population

    SBC: NAJIT TECHNOLOGIES INC            Topic: NIAID

    ABSTRACT Yellow fever virus (YFV) represents a mosquito-borne emerging/re-emerging human pathogen that causes 20- 50% mortality and is endemic in andgt;40 countries. The current live attenuated YFV vaccine was developed in 1936 and following the establishment of a virus seed lot system, it has not been modified or otherwise improved in over 50 years. According to the CDC, this vaccine causes 47 se ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Advancing Human Health by Lowering Barriers to Electrophysiology in Genetic Model Organisms

    SBC: NEMAMETRIX, INC            Topic: 300

    Project Summary The nematode worm Caenorhabditis elegans has proven valuable as a model for many high impact medical conditionsThe strength of Celegans derives from the extensive homologies between human and nematode genesand the many powerful tools available to manipulate genes in Celegansincluding expressing human genesResearchers utilizing medical models based on Celegans have converged on two ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Factor XI inhibitor for thrombosis

    SBC: ARONORA INC            Topic: NHLBI

    Project Summary Although potent antithrombotic agents are availableall of these drugs inadvertently target vital hemostatic molecular mechanismsresulting in dose limiting hemorrhagic toxicity that restrict their useDue to a lack of safe thromboprophylaxisthrombotic blood vessel occlusions continue to be extremely prevalentand result in a wide range of severe disease conditions that remain the lead ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. A Double Balloon Catheter for the Treatment of Intussusception in Children

    SBC: SEALCATH LLC            Topic: NICHD

    PROJECT SUMMARY ABSTRACT During Phase ISealCathLLC will test the feasibility of its innovative Double Balloon CatheterDBCwhich the United States Utility Patent application was approved on Augustand is in the process of issuing a patentLicensed from the Medical University of South Carolinathis DBC will be commercialized in Phase III as the trademarked nameCephus Catheterwith targeted end users bein ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Mobility Rehab: A Biofeedback System for Mobility Rehabilitation for Older Adults

    SBC: APDM, INC.            Topic: NIA

    Project Summary Mobility limitations including gait and balance impairments are common in older adultsespecially those with neurological de citsGait and balance impairments are a major cause of falls and reduced quality of lifeAlthough laboratory studies show that biofeedback during exercise training can improve motor performancephysical therapists do not have access to an overground gait biofeedb ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. HLS-Affordable, quantitative microchip-electrophoresis for sickle cell disease screening

    SBC: HEMEX HEALTH INC            Topic: NHLBI

    PROJECT SUMMARY Sickle Cell DiseaseSCDaffectsAmericans and more thanmillion people globallyprimarily in economically disadvantaged populationsIt is estimated that nearlyof children born with SCD in these areas die before the age of fivealthoughcould be saved through simplecost effective treatments if diagnosed early according to World Health OrganizationEarly diagnosis of SCD remains a challenge i ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. NeuroPredict, A screening assay for chemicals that affect the differentiation of human neural cells.

    SBC: NZUMBE INC            Topic: NIEHS

    ABSTRACT A growing human health concern is that exposure to chemicals in our environment harms the highly vulnerable period of human brain developmentIndeedincreasing evidence shows that even simpleacute exposures of the developing brain to select agents cause profound neurological disorders such as epilepsyautism and intellectual disabilityDespite this vulnerabilitythe reliablehigh throughput ide ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government